Phenominer Database Results (28 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Duration Post Insult Time Value Record ID Study ID
DA/Ztm post-insult time to onset of experimental autoimmune encephalomyelitis spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 13.0 d 2.0 6.0 in vivo visual assessment 0.0 0 69952 1258
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 100.0 % in vivo visual assessment 0.0 0 69624 1161
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69722 1162
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 14.2 d 0.4 1.26 in vivo visual assessment 0.0 0 69790 1162
DA/Ztm post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 14.2 d 1.1 3.48 in vivo visual assessment 0.0 0 69792 1162
DA/Ztm post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 median 14.0 d in vivo visual assessment 0.0 0 69637 1161
DA/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 10 100.0 % in vivo visual assessment 0.0 0 69724 1162
DA/Ztm percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 56.0 % in vivo visual assessment 0.0 0 69951 1258
DA/Ztm percentage of study population developing acute experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 22.0 % in vivo visual assessment 0.0 0 69950 1258
DA/Ztm experimental autoimmune encephalomyelitis duration spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 9.0 d 2.67 8.0 in vivo visual assessment 0.0 0 69953 1258
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 12 14.5 d 0.5 1.73 in vivo visual assessment 0.0 0 69777 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 16 88.0 % in vivo visual assessment 0.0 0 69706 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 9 100.0 % in vivo visual assessment 0.0 0 69714 1162
DA/Ztm subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 50.0 % in vivo visual assessment 0.0 0 69631 1161
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 100.0 % in vivo visual assessment 0.0 0 69625 1161
DA/Ztm post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 median 14.0 d in vivo visual assessment 0.0 0 69636 1161
DA/Ztm post-insult time to onset of experimental arthritis pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 17 12.1 d 0.3 1.24 in vivo visual assessment 0.0 0 69784 1162
DA/Ztm post-insult time to onset of experimental arthritis squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 13.0 d 0.4 1.55 in vivo visual assessment 0.0 0 69773 1162
DA/Ztm post-insult time to onset of experimental arthritis squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 9 14.0 d 0.7 2.1 in vivo visual assessment 0.0 0 69788 1162
DA/Ztm post-insult time to onset of experimental arthritis type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait male 120 days-200 days 9 15.2 d 0.2 0.6 in vivo visual assessment 0.0 0 69782 1162
DA/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time spinal cord homogenate (10 mg) Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8 central nervous system integrity trait male 56 days-103 days 9 78.0 % in vivo visual assessment 0.0 0 69949 1258
DA/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70 days-145 days 36 72.0 % in vivo visual assessment 0.0 0 69969 1279
DA/Ztm percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 17 100.0 % in vivo visual assessment 0.0 0 69716 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 9 100.0 % in vivo visual assessment 0.0 0 69720 1162
DA/Ztm subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 38.0 % in vivo visual assessment 0.0 0 69630 1161
DA/Ztm post-insult time to onset of experimental arthritis Freund's complete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 16 14.9 d 0.5 2.0 in vivo visual assessment 0.0 0 69775 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 100.0 % in vivo visual assessment 0.0 0 69703 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 12 100.0 % in vivo visual assessment 0.0 0 69709 1162